M Buyse

Summary

Country: Belgium

Publications

  1. ncbi The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials
    M Buyse
    International Institute for Drug Development, Brussels, and Limburgs Universitair Centrum, Diepenbeek, Belgium
    Stat Med 18:3435-51. 1999
  2. ncbi Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer
    M Buyse
    International Institute for Drug Development, Brussels, Belgium
    Lancet 356:373-8. 2000
  3. ncbi Should Dukes' B patients receive adjuvant therapy? A statistical perspective
    M Buyse
    International Institute for Drug Development, Brussels, Belgium
    Semin Oncol 28:20-4. 2001
  4. ncbi Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11
    A Di Leo
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 15:545-9. 2004
  5. ncbi Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
    H Piessevaux
    Service de Gastro Enterologie, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Ann Oncol 20:1375-82. 2009
  6. ncbi Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer
    J L Liénard
    International Drug Development Institute IDDI, Brussels, Belgium
    Clin Trials 3:486-92. 2006
  7. ncbi Criteria for the validation of surrogate endpoints in randomized experiments
    M Buyse
    International Institute for Drug Development, Brussels, Belgium
    Biometrics 54:1014-29. 1998

Collaborators

Detail Information

Publications7

  1. ncbi The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials
    M Buyse
    International Institute for Drug Development, Brussels, and Limburgs Universitair Centrum, Diepenbeek, Belgium
    Stat Med 18:3435-51. 1999
    ..Many instances of fraud in clinical trials, although morally reprehensible, have a negligible impact on the trial's scientific conclusions...
  2. ncbi Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer
    M Buyse
    International Institute for Drug Development, Brussels, Belgium
    Lancet 356:373-8. 2000
    ..However, improvements in response rates have not always translated into significant survival benefits. Doubts have therefore been raised about the usefulness of tumour response as a clinical endpoint...
  3. ncbi Should Dukes' B patients receive adjuvant therapy? A statistical perspective
    M Buyse
    International Institute for Drug Development, Brussels, Belgium
    Semin Oncol 28:20-4. 2001
    ....
  4. ncbi Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11
    A Di Leo
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 15:545-9. 2004
    ..The adequacy of overall survival (OS) as study end point in phase III trials for advanced solid tumors is questionable. The present review highlights the limits of OS as study end point to evaluate the efficacy of new drugs...
  5. ncbi Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
    H Piessevaux
    Service de Gastro Enterologie, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Ann Oncol 20:1375-82. 2009
    ..Early radiological tumor shrinkage may be associated with better long-term outcome in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab. We aimed at validating this in a large and independent series...
  6. ncbi Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer
    J L Liénard
    International Drug Development Institute IDDI, Brussels, Belgium
    Clin Trials 3:486-92. 2006
    ..To provide empirical evidence on the impact of on-site initiation visits on the following outcomes: patient recruitment, quantity and quality of data submitted to the trial coordinating office, and patients' follow-up time...
  7. ncbi Criteria for the validation of surrogate endpoints in randomized experiments
    M Buyse
    International Institute for Drug Development, Brussels, Belgium
    Biometrics 54:1014-29. 1998
    ..Linear models are employed for continuous endpoints. In order to be of practical value, the validation of surrogate endpoints is shown to require large numbers of observations...